34146-68-4

Basic information

• Product Name: 8-methoxy-1,2,3,4-tetrahydroisoquinoline
• Synonyms: 8-methoxy-1,2,3,4-tetrahydroisoquinoline;m90103
• CAS NO: 34146-68-4
• Molecular Formula: C₁₀H₁₃NO
• Molecular Weight: 163.22
• Mol File: 34146-68-4.mol
• Article Data: 13

Chemical Properties

• Melting Point: 38-39℃
• Boiling Point: 73-76℃ (0.065 Torr)
• Flash Point: 113.001 °C
• Appearance: /
• Density: 1.044 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.532
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.57±0.20(Predicted)
• CAS DataBase Reference: 8-methoxy-1,2,3,4-tetrahydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-methoxy-1,2,3,4-tetrahydroisoquinoline(34146-68-4)
• EPA Substance Registry System: 8-methoxy-1,2,3,4-tetrahydroisoquinoline(34146-68-4)

Safety Data

• Hazardous Substances Data: 34146-68-4(Hazardous Substances Data)

Usage

General Description

8-methoxy-1,2,3,4-tetrahydroisoquinoline is a chemical compound with a molecular formula of C10H13NO and a molecular weight of 163.22 g/mol. It is a heterocyclic compound that contains a tetrahydroisoquinoline core structure and a methoxy group attached to the 8th carbon atom. 8-methoxy-1,2,3,4-tetrahydroisoquinoline has been studied for its potential pharmacological activities, including its ability to act as a dopamine D2 receptor agonist. It has also been investigated for its potential role in the treatment of Parkinson's disease and other neurodegenerative disorders. Additionally, 8-methoxy-1,2,3,4-tetrahydroisoquinoline has been found to exhibit antioxidant and neuroprotective properties, making it a subject of interest in the development of new therapeutic agents.

InChI:InChI=1/C10H13NO/c1-12-10-4-2-3-8-5-6-11-7-9(8)10/h2-4,11H,5-7H2,1H3

Upstream product

• 74904-29-3 8-methoxy-3,4-dihydroisoquinolin-1(2H)-one 
• 29969-40-2 2-formyl-1,2,3,4-tetrahydro-8-methoxyisoquinoline 
• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 135-02-4 ortho-anisaldehyde 
• 212184-90-2 (2-Methoxy-benzyl)-(2-phenylsulfanyl-ethyl)-amine 
• 212184-84-4 8-Methoxy-4-phenylsulfanyl-3,4-dihydro-1H-isoquinoline-2-carbaldehyde 
• 212184-94-6 N-(2-Methoxy-benzyl)-N-(2-phenylsulfanyl-ethyl)-formamide 
• 212184-77-5 N-(2-Benzenesulfinyl-ethyl)-N-(2-methoxy-benzyl)-formamide 
• 15184-99-3 N,N-dimethyl-3-methoxybenzylamine 
• 81625-31-2 2-(ethoxycarbonyl)-3-methoxyphenylacetonitrile 
• 81625-32-3 2-(2-Amino-ethyl)-6-methoxy-benzoic acid ethyl ester 
• 81625-29-8 N,N-dimethyl-2-(ethoxycarbonyl)-3-methoxybenzylamine 
• 81625-30-1 2-(ethoxycarbonyl)-3-methoxybenzyl chloride 

Downstream Products

• 1723-70-2 8-methoxyisoquinoline 
• 24693-44-5 8-methoxy-3,4-dihydroisoquinoline 
• 81625-36-7 2-benzoyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-39-0 2-(4-phenylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-37-8 2-(4-tert-butylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 32999-37-4 1,2,3,4-tetrahydroisoquinoline-8-ol 
• 464900-21-8 8-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 81625-35-6 1-hydroxy-2-benzoyl-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-40-3 1-<4-(benzyloxy)benzyl>-2-(4-tert-butylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-41-4 1-<4-(benzyloxy)benzyl>-2-(4-phenylbenzoyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-20-9 1-(3,4-dimethoxybenzyl)-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 81625-22-1 1-<4-(benzyloxy)benzyl>-8-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 508235-82-3 5-(3,4-Dimethoxybenzylamino)-2-(2-furyl)-8-(8-methoxy-1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine 
• 73903-30-7 8-Methoxy-2-methyl-1,2,3,4-tetrahydroisochinolin 

Relevant articles and documents

Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor

The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)

UREA PEPTOID BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (I).

Structure-Based Design and Discovery of New M2 Receptor Agonists

Muscarinic receptor agonists are characterized by apparently strict restraints on their tertiary or quaternary amine and their distance to an ester or related center. On the basis of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explored potential agonists that lacked the highly conserved functionalities of previously known ligands. Using structure-guided pharmacophore design followed by docking, we found two agonists (compounds 3 and 17), out of 19 docked and synthesized compounds, that fit the receptor well and were predicted to form a hydrogen-bond conserved among known agonists. Structural optimization led to compound 28, which was 4-fold more potent than its parent 3. Fortified by the discovery of this new scaffold, we sought a broader range of chemotypes by docking 2.2 million fragments, which revealed another three micromolar agonists unrelated either to 28 or known muscarinics. Even pockets as tightly defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based design and the discovery of new chemotypes.